Tarsus to acquire Alkeus, betting on a first-ever Stargardt disease drug
What's the deal? Tarsus Pharmaceuticals has signed a definitive agreement to acquire Alkeus Pharmaceuticals, a privately held biotech developing gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease. The Irvine, California-based company announced the deal on August 6, 2026.
Why this matters: Stargardt disease is an inherited retinal condition that often begins in childhood and progressively destroys central vision. More than 36,000 people in the US have been diagnosed, and there are currently no FDA-approved therapies.
What's the endgame? ALK-001 is designed to reduce the accumulation of toxic vitamin A dimers that damage retinal cells, while preserving the normal visual cycle. The therapy has treated over 400 individuals to date and carries more than seven years of long-term tolerability data.
Why now? The acquisition builds on Tarsus's strategy to become a leading eye care company, complementing its retina work through IRX-101 and its earlier acquisition of iRenix MedicalDealroom has a profile for this one. Try Dealroom →. Top-line Phase 3 NORTHSTAR data is expected in the second half of 2029.
By the numbers: ALK-001 has received Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations from the FDA, positioning it as what Tarsus calls a potential blockbuster.
"We believe gildeuretinol has the potential to be a transformational medicine for Stargardt disease," said Bobby Azamian, chief executive officer and chairman of Tarsus.
Michel Dahan, president and chief executive officer of Alkeus, pointed to the drug's tolerability profile as "an especially important consideration for a therapy that may be used for many years."
What could go wrong? The program remains in Phase 3, with pivotal data still three years out. If NORTHSTAR fails to confirm the encouraging early findings, the acquisition's central asset loses much of its value.
The signal: Tarsus is assembling a retina-focused pipeline through targeted acquisitions, wagering that addressing the underlying biology of rare, undertreated eye diseases can carve out a defensible leadership position in eye care.
Read more: GlobeNewswire
Image credit: illustir
